FEMY vs. NMTC, MDAI, ICU, RVP, IINN, AKLI, CODX, GBS, POCI, and TTOO
Should you be buying Femasys stock or one of its competitors? The main competitors of Femasys include NeuroOne Medical Technologies (NMTC), Spectral AI (MDAI), SeaStar Medical (ICU), Retractable Technologies (RVP), Inspira Technologies Oxy B.H.N. (IINN), Akili (AKLI), Co-Diagnostics (CODX), GBS (GBS), Precision Optics (POCI), and T2 Biosystems (TTOO). These companies are all part of the "medical" sector.
NeuroOne Medical Technologies (NASDAQ:NMTC) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
In the previous week, NeuroOne Medical Technologies had 2 more articles in the media than Femasys. MarketBeat recorded 6 mentions for NeuroOne Medical Technologies and 4 mentions for Femasys. NeuroOne Medical Technologies' average media sentiment score of 0.09 beat Femasys' score of -0.12 indicating that Femasys is being referred to more favorably in the news media.
NeuroOne Medical Technologies received 41 more outperform votes than Femasys when rated by MarketBeat users. Likewise, 71.59% of users gave NeuroOne Medical Technologies an outperform vote while only 64.71% of users gave Femasys an outperform vote.
NeuroOne Medical Technologies has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.76, suggesting that its share price is 376% less volatile than the S&P 500.
NeuroOne Medical Technologies presently has a consensus target price of $2.20, suggesting a potential upside of 103.70%. Femasys has a consensus target price of $11.67, suggesting a potential upside of 818.64%. Given NeuroOne Medical Technologies' higher possible upside, analysts clearly believe Femasys is more favorable than NeuroOne Medical Technologies.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 16.4% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
NeuroOne Medical Technologies has higher revenue and earnings than Femasys. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.
NeuroOne Medical Technologies has a net margin of -343.55% compared to NeuroOne Medical Technologies' net margin of -1,420.59%. NeuroOne Medical Technologies' return on equity of -104.06% beat Femasys' return on equity.
Summary
Femasys beats NeuroOne Medical Technologies on 9 of the 17 factors compared between the two stocks.
Get Femasys News Delivered to You Automatically
Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
